a public good project by the
Synthesis
Company
of California

© 2026

Neil Stahl | doi.page

0 works0 citations0 h-index

Neil Stahl

University of California San Diego(US)Arthritis and Rheumatism Associates(US)

Publications by Year

Research Areas

SARS-CoV-2 and COVID-19 Research, Asthma and respiratory diseases, Prion Diseases and Protein Misfolding, COVID-19 Clinical Research Studies, Cytokine Signaling Pathways and Interactions

Most-Cited Works

→ Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration(2012)2,431 cited
→ Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis(2016)1,987 cited
→ Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma(2018)1,869 cited
→ REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19(2020)1,786 cited
→ Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies(2020)1,467 cited
→ Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail(2020)1,417 cited

→ Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials(2019)

1,404 cited

→ Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis(2014)1,388 cited

→ Dupilumab in Persistent Asthma with Elevated Eosinophil Levels(2013)1,301 cited

→ Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial(2017)1,211 cited